Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mirzotamab clezutoclax
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Mirzotamab clezutoclax is a first-in-class antibody-drug conjugate (ADC) developed for the treatment of advanced solid tumors. It consists of an anti–B7-H3 (CD276) monoclonal antibody, a solubilizing linker, and a BCL-XL inhibitor payload. The drug specifically targets the immunoregulatory protein B7-H3 on tumor cells and delivers the BCL-XL inhibitor directly to these cells via the ADC mechanism. This targeted approach aims to inhibit tumor growth by inducing apoptosis in cancer cells that overexpress B7-H3 while minimizing systemic toxicity associated with direct BCL-XL inhibition. Preclinical studies have shown synergy with other anticancer agents, and clinical trials are ongoing in relapsed/refractory solid tumors including small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and hormone receptor-positive breast cancer.
- Other names
- Mirzotamab-AbbVie
02
Targets
B7-H3BCL2L1 (B-cell lymphoma-extra large protein)
Beyond the preview
Go deeper on mirzotamab clezutoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mirzotamab clezutoclax.